Saturday 17 October 2026
Export XAGE’s income statement to Excel — free account
Longevity Health Holdings, Inc.
XAGE Consumer Defensive Household & Personal Products
Longevity Health Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, up 3,702.8% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS grew 51.3% and free cash flow grew 73.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.11
0.00
0.00%
Follow XAGE
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 1.58 | 0.22 |
Altman Z-Score |
— | — | — | — | (80.00) | (56.91) |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (197.81) | (141.83) |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (7.72) | (1.40) |
Beneish M-Score |
— | — | — | — | — | 22.85 |
P/B ratio |
— | — | — | — | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | 1.93 | 0.64 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (1.88) | (0.37) |
EV/FCF |
— | — | — | — | (1.86) | (0.36) |
Quick Ratio |
— | 2.35 | 0.02 | 0.08 | 0.08 | 0.09 |
Current Ratio |
— | 2.95 | 0.08 | 1.63 | 0.16 | 0.25 |
Net Debt/EBITDA |
— | 1.66 | 0.04 | 0.50 | 0.03 | 0.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
Operating CF/Net income |
— | 1.37 | 0.36 | 0.52 | 0.38 | 0.48 |
Capex/Depreciation |
— | — | 0.00 | (0.19) | 0.00 | (0.07) |
Interest Coverage |
— | (57.70) | (3.23) | (6.96) | (169.44) | (390.53) |
| — | 0.00% | 45.16% | 247.23% | (103.50%) | 130.54% | |
| — | (0.42%) | (12.23%) | (49.08%) | (31.70%) | (359.56%) | |
ROIC |
— | 0.00% | 0.00% | (17.01%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (51.21%) | 149.31% | (65.56%) | 215.68% | 117.75% |
Average Days of Receivables |
— | — | — | 0.00 | 2,219.75 | 6.96 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 2,096.02% | 41.24% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 7,762.82% | 383.46% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 1,644.14% | 36.22% |
Graham Net Nets |
— | — | — | — | (0.88) | (14.65) |
Graham Number |
— | — | — | — | 46.59 | 21.62 |
Earnings Yield |
— | — | — | — | (174.19%) | (1,686.67%) |
Free Cash Flow Yield |
— | — | — | — | (65.89%) | (779.59%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.07 | 1.34 |
Operating CF per Share |
— | (3.38) | (58.61) | (22.75) | (5.47) | (2.33) |
Capex per Share |
— | 0.00 | (0.12) | (0.08) | 0.00 | (0.01) |
Free Cash Flow per Share |
— | (3.38) | (58.73) | (22.83) | (5.47) | (2.34) |
Cash per Share |
— | 5.80 | 2.19 | 7.94 | 0.22 | 0.49 |
Shareholders Equity per Share |
— | (35.70) | (108.97) | 67.44 | (6.62) | (4.10) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (35.70) | (108.97) | 67.44 | (6.62) | (4.10) |
Free Cash Flow |
— | (0.45) | (3.44) | (8.38) | (3.89) | (3.34) |
Working Capital |
— | 0.64 | (6.69) | 24.40 | (4.92) | (5.97) |
Capital Expenditures |
— | — | (0.01) | (0.03) | — | (0.01) |
Net Current Asset Value |
— | (159.21) | (7.52) | 23.70 | (5.23) | (6.28) |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.01 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
— | — | 8.97 | 0.83 | 1.90 | 2.12 |
Cash ROIC |
— | 11.31% | 55.01% | (30.29%) | 85.46% | 64.79% |
Accounts Receivable Turnover |
— | — | — | — | 0.20 | 11.17 |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.19 |
Inventory Turnover |
— | — | — | — | 0.00 | 1.53 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 231,438.52 | 2,005.43 |
Days of Inventory on Hand |
— | — | — | — | 6,199.30 | 429.65 |
Average Receivables |
— | — | — | — | 0.26 | 0.17 |
Average Payables |
— | — | — | 3.28 | 4.24 | 4.28 |
Average Inventory |
— | — | — | — | — | 0.54 |
Average Assets |
— | 77.71 | 78.59 | 32.85 | 32.71 | 1.92 |
Average Common Equity |
— | — | (21.28) | (6.52) | 10.02 | (5.29) |
Columns are period end dates